GT Biopharma Inc reports results for the quarter ended in December - Earnings Summary

GT Biopharma

28/03/2024 12:00

* GT Biopharma Inc  GTBP.OQ  reported a quarterly adjusted
loss of
$2.19​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of
$-5.40.  The lone analyst forecast for the quarter was for a
loss of $2.70 per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * GT Biopharma Inc's reported EPS for the quarter was a loss
of
$2.19​.
    * The company reported a quarterly loss of $2.96 million.
    * GT Biopharma Inc shares had fallen by 42.9% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for GT Biopharma Inc
is $150.00 
This summary was machine generated from LSEG data March 28 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -2.70          -2.19          Beat
 Sep. 30 2023      -3.00          -1.80          Beat
 Jun. 30 2023      -3.00          -1.50          Beat
 Mar. 31 2023      -4.35          -0.30          Beat